Showing 51 to 75 of 136 Results
Page 1 | 2 | 3 | 4 | 5 | 6
Gore Joins Vascular and Endovascular Leaders in Honoring 2012 Pioneers in Performance in Europe
16 April 2012 - Leading Practitioners and Researchers from Europe Commended for Expanding Treatment Options for At-Risk Patients

First Patient Implanted in Investigational Study for Self Sealing GORE® ACUSEAL Vascular Graft
12 August 2010 - Study Gauges Benefits for End Stage Renal Disease Patients During Hemodialysis

Gore Receives FDA Approval for Next Generation of Large Diameter GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
21 July 2009 - Improved design now available with lower profile delivery system for use in iliac arteries.

Gore Joins Vascular and Endovascular Leaders in Recognizing the 2014 Pioneers in Performance for North America
19 November 2014 - Leading Practitioners and Researchers from North America Commended for Commitment to Advancing Vascular and Endovascular Therapy

New 10 cm GORE® Hybrid Vascular Graft Delivers Unprecedented Versatility
14 November 2012 - Increased Length of Nitinol Reinforced Section Allows for Access to Deeper Vessels, Extends Landing-Zone Positioning Options

First Patient Enrolled in GORE® TAG® Thoracic Branch Endoprosthesis Early Feasibility Study
28 April 2015 - First Early Feasibility Study of a Gore Device Will Assess Treatment of Aortic Arch Aneurysms

Gore Announces First Implant of Next Generation Conformable GORE TAG® Thoracic Endoprosthesis in US Clinical Trial for the Treatment of Thoracic Aortic Aneurysms
20 October 2009 - W. L. Gore & Associates (Gore) today announced the first human implants of the next generation Conformable GORE TAG® Thoracic Endoprosthesis for the treatment of thoracic aortic aneurysms (TAAs)

Gore Announces FDA Approval of Next Evolution of GORE® VIABAHN® Endoprosthesis
17 February 2011 - Lower profile delivery system in the US provides more options for endoluminal bypass

Gore Launches Early Cannulation Capable GORE® ACUSEAL Vascular Graft
19 November 2013 - Results of early cannulation clinical trial presented at the 2013 VEITHsymposium

Gore receives FDA approval for GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
05 September 2007 - Heparin-Bonded Endoprosthesis for Superficial Femoral Artery Interventions

SVS and Gore Support Increasing Numbers of Women in Vascular Surgery
23 May 2012 - Women’s Leadership to Take Spotlight at the Society for Vascular Surgery 2012 Vascular Annual Meeting


W. L. Gore & Associates takes on peripheral vascular disease at Vascular Interventional Advances (VIVA) Conference
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).

First Patients Enrolled in Gore Thoracoabdominal Aortic Aneurysm Clinical Study
13 November 2014 - Device offers first and only complete “off-the-shelf” endovascular system specifically designed to treat aortic aneurysms involving visceral branch vessels

Gore REDUCE Clinical Study Principal Investigators Respond to Recent RESPECT Clinical Trial and PC Trial Results
15 November 2012 - Gore REDUCE Clinical Study Investigators Implored to Continue Enrollment, Drive 'Diligent Continuation of Study'

Study Confirms GORE® BIO-A® Tissue Reinforcement a Proven Alternative to Biologics in Hernia Repair
28 April 2015 - Two-year study demonstrates improved patient satisfaction with Gore material

W. L. Gore & Associates enrolls first patient in study of 45 mm GORE TAG® Thoracic Endoprosthesis
20 February 2007 - W. L. Gore & Associates announced today that the first patient has been enrolled in a US Food and Drug Administration (FDA) approved IDE study for the 45 mm* GORE TAG® Thoracic Endoprosthesis for treatment of aneurysms of the descending thoracic aorta.

Gore Launches Lower Profile GORE® EXCLUDER® AAA Endoprosthesis Contralateral Leg Components in US and Europe
11 March 2013 - Addition to Series of Reduced Profile GORE® EXCLUDER® Devices Launching This Year

Gore Receives CE Mark for GORE® PROPATEN® Vascular Graft for Hemodialysis Access
22 February 2011 - Unique Vascular Graft Transcends Mechanical Solutions for Dialysis Access

GORE® C3 Delivery System Approved In Japan
03 December 2013 - System Enables Physicians and Interventionalists to Reposition GORE® EXCLUDER® AAA Endoprosthesis for Ideal Placement in Treating Abdominal Aortic Aneurysms

Gore Applauds Medicare Announcement to Reclassify Endovascular Abdominal Aneurysm Repairs
03 August 2015 - Decision comes after two-year effort to improve the alignment of payment with cost of treatment for abdominal aortic aneurysms

Gore Announces Broadened FDA Indication for GORE VIABAHN® Endoprosthesis for Iliac Occlusive Disease
17 September 2008 - Only Stent-Graft Approved for Treatment of Both Iliac and Superficial Femoral Arteries

Gore Participates in FDA Circulatory System Devices Advisory Panel Meeting
07 June 2012 - Focus on Safety and Effectiveness of GORE® HELEX® Septal Occluder for Closure of Atrial Septal Defect (ASD)

Gore Delivers New Choice for Complex Soft Tissue Reinforcement
04 October 2010 - Economical Alternative to Biologics, Now In Larger Sizes

Gore Receives CE Mark for Longer Length GORE® VIABAHN® Endoprosthesis
01 July 2010 - Longest stent-graft ever introduced in Europe for SFA endoluminal bypass

Gore Receives Health Canada Approval for GORE® VIABAHN® Endoprosthesis Innovations, Treating Peripheral Vascular Disease
04 February 2015 - Longer and Lower Profile Options Now Available in Canada to Treat More Patient Anatomies

Improved GORE® DrySeal Sheath with Hydrophilic Coating Allows for Smooth and Minimally Invasive Endovascular Repair
18 December 2012 - Engineered to Increase Sheath Lubricity and Minimize Coating Particulation for Easier Insertion and Removal in Treatment of Patients with AAA and TAA

GORE® EXCLUDER® Iliac Branch Endoprosthesis is First Dedicated System of Its Kind Registered in Australia and New Zealand
13 May 2015 - First Successful Implants Providing Endovascular Repair to Iliac Arteries Completed in Australia

Gore Receives European CE Mark Approval for Next Generation Conformable GORE TAG® Thoracic Endoprosthesis
07 November 2009 - First human implant highlights innovative, conformable design of GORE TAG® Thoracic Endoprosthesis

Nominees Announced for 2013-2014 Pioneers in Performance Awards for Europe; Online Voting Opens at PioneersInPerformance.com
06 April 2013 -

Awards Program Sponsored by W. L. Gore & Associates Honors Medical Specialists Advancing Therapy and Improving Patient and Clinical Performance Through Active Collaboration



FDA Approves GORE® VIABAHN® Endoprosthesis for Revision of the Arteriovenous Access
11 December 2013 - Flexibility and Durability to Aid Hemodialysis Patients

VIBRANT Study of GORE VIABAHN® Endoprosthesis Completes Enrollment
01 January 2008 - Randomized Trial to Assess Patency of Covered Stents vs. Nitinol Stents for the Treatment of Vascular Disease

W. L. Gore & Associates takes on peripheral vascular disease at Vascular Interventional Advances (VIVA) Conference
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).


Gore Launches Study of Early TIPS Therapy for Ascites Patients
01 November 2010 - Experts Call for Fresh Look at Transjugular Intrahepatic Portosystemic Shunt (TIPS) Therapy for Liver Disease Patients

Gore Prevails in Heart Device Patent Infringement Suit
05 August 2013 - W. L. Gore & Associates (Gore) today announced a favorable ruling involving the GORE® HELEX® Septal Occluder.

Gore Receives FDA Approval for Conformable GORE® TAG® Thoracic Endoprosthesis
16 November 2011 - Durable ePTFE Endoprosthesis Designed for Endovascular Repair of the Descending Thoracic Aorta Provides Conformability without Compromise

Gore Provides Update on Patent Foramen Ovale (PFO) Stroke Study
08 July 2010 - Gore Reaffirms Commitment to Multi-National, Randomized Study on PFO Closure in Stroke Patients using GORE® HELEX Septal Occluder Versus Medical Management

Gore Completes Primary Enrollment for the Gore EXCLUDER® Iliac Branch Clinical Study
17 February 2015 - 62 patients enrolled in US investigational device exemption clinical study to assess first complete, low-profile system for managing common iliac artery aneurysms or aorto-iliac aneurysms

Gore Receives FDA Approval for New GORE® EXCLUDER® AAA Endoprosthesis Components
14 January 2013 - Expanded Treatment Options for Abdominal Aortic Aneurysms Provide More Patients with Access to Minimally Invasive Endovascular Repair

Gore Global Registry for Endovascular Aortic Treatment Enrolls 3,000 Patients
18 June 2015 - Midpoint findings to be released at 2015 Vascular Annual Meeting in Chicago

Gore Recognizes Physicians as “Pioneers in Performance” for Exceptional Work in the Field of Endovascular Therapy
17 February 2009 - Leading practitioners and researchers from around the world commended for expanding treatment options for at-risk patients

Gore Joins Vascular and Endovascular Physicians in Honoring 2013 Pioneers in Performance Winners for Latin America
29 April 2013 - Leading Practitioners and Researchers from Mexico, Central and South America CICE 2013

Gore Showcases New Endovascular Repair Simulation Technology at VIVA
18 October 2011 - Physicians Simulate Real Patient Cases Ushering New Era of Procedure Preparation

First Australian Patients Enrolled in Gore Global Registry for Endovascular Aortic Treatment
20 March 2012 - Royal Prince Alfred Hospital First in Australia


W. L. GORE & Associates Named a Top U.S. Workplace
16 January 2014 - Company has appeared in every listing of the “100 Best Companies to Work For”

Gore and AAAneurysm Outreach Partner to Increase Early Detection of Abdominal Aortic Aneurysm (AAA)
28 January 2014 - New Campaign Will Employ Awareness, Community Outreach, and Patient Screening to Fight AAA

First Patient Enrolled in Study of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface for Lower Limb Peripheral Vascular Disease
18 October 2007 - The first patient to enter a post-market evaluation designed to collect important data about the performance of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface in treating lower limb peripheral vascular disease (PVD), has undergone a successful implant.

Gore Announces First Patient Enrolled in Gore REVISE Clinical Study
17 September 2008 - IDE Study to Compare Performance of GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to Percutaneous Transluminal Angioplasty (PTA)

England National Institute for Health Research Stroke Research Network Adopts Gore REDUCE Clinical Study
19 June 2012 - Study Investigates Device Closure of Patent Foramen Ovale (PFO) in Stroke Reduction.

Gore Reaffirms Commitment to Stroke Study, Launches Online Resource
15 November 2010 - Cardiology and Neurology Investigators Support Continued Study of Patent Foramen Ovale (PFO)

First Patient Enrolled in Gore® SCAFFOLD Clinical Study for Carotid Stenting
12 September 2013 - Pivotal Multicenter Investigational Study Begins at Medical University of South Carolina (MUSC), Evaluating Safety and Efficacy of Innovative GORE® Carotid Stent

Nominees Announced for 2011-2012 Pioneers in Performance Awards for the United States; Online Voting Opens at www.PioneersInPerformance.com
16 November 2011 - Awards Program Sponsored by W. L. Gore & Associates Honors Medical Specialists Advancing Therapy and Improving Patient and Clinical Performance Through Active Collaboration

Gore Launches Improved GORE® HELEX Delivery System in Europe
12 July 2010 - W. L. Gore & Associates is pleased to announce the availability of an improved iteration of the GORE® HELEX Septal Occluder. The rollout of the improvement will begin in Europe immediately, and its availability will open up to other markets pending respective regulatory approvals.


Gore REDUCE Clinical Study Completes Enrollment
25 February 2015 - Study of Closure of Patent Foramen Ovale (PFO) in Stroke Patients Reaches Major Milestone

Improved GORE® DrySeal Sheath with Hydrophilic Coating Launches in Europe
23 January 2013 - New Product Engineered to Increase Sheath Lubricity, Minimize Coating Particulation for Easier Insertion and Removal in Treating Patients with AAA and TAA

Global Vascular Thought Leaders Document Shift toward Individualizing Patient Care in Surgical Bypass
17 June 2015 - Presentations and Discussions from the Surgical Bypass Summit Available at www.surgicalbypass.com

Gore REVISE Study Receives Approval From FDA
07 April 2008 - The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface to revise arterio-venous grafts at the venous anastomosis in hemodialysis patients.

Gore Medical Receives National Honor for Operational Excellence
20 June 2013 - W. L. Gore & Associates named as a winner of the eighth annual Pinnacle Award

Gore Acquires Intellectual Property of NMT Medical, Inc.
19 October 2011 - CLOSURE I Trial Data May Create Better Clinical Understanding of Patent Foramen Ovale (PFO) in Stroke Patients

GORE® Hybrid Vascular Graft Commercially Available in the United States
01 June 2011 - W. L. Gore & Associates today is announcing commercial availability in the US of the GORE® Hybrid Vascular Graft.

Nominees Announced for 2011 Pioneers in Performance Awards for Europe; Online Voting Opens at www.PioneersInPerformance.com
11 April 2011 - Awards Program Sponsored by W. L. Gore & Associates Honors Medical Specialists Advancing Therapy and Improving Patient and Clinical Performance Through Active Collaboration


Gore REVISE Clinical Study Demonstrates Superiority of GORE VIABAHN Endoprosthesis
20 February 2014 - GORE Device Outperforms Standard Treatment Option for Stenoses or Thrombotic Occlusions

W. L. Gore & Associates takes on peripheral vascular disease at Vascular Interventional Advances (VIVA) Conference
11 October 2007 - W. L. Gore & Associates recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD).

First Patient Enrolled in Study of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface for Lower Limb Peripheral Vascular Disease
18 October 2007 - The first patient to enter a post-market evaluation designed to collect important data about the performance of the GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface in treating lower limb peripheral vascular disease (PVD), has undergone a successful implant.

Gore Announces New Configuration of GORE BIO-A® Tissue Reinforcement for Hiatal Hernia Repair
15 June 2008 - Gore adds thinner, more flexible, custom size bioabsorbable product

Clinical Investigators Address Confusion Over Study of Patent Foramen Ovale (PFO) in Stroke Patients
13 December 2010 - W. L. Gore & Associates today released the following statement from the Gore REDUCE Clinical Study Principal Investigators on behalf of the Gore REDUCE Clinical Study Steering Committee in response to the recent CLOSURE I results presentation.

Gore Receives First FDA Approval for Endovascular Repair of Aortic Dissection
11 September 2013 - Conformable GORE® TAG® Thoracic Endoprosthesis First to Receive Indication for Aneurysm, Trauma and Dissection

New GORE® EXCLUDER® AAA Endoprosthesis Sizing Options Available
29 November 2011 - Broader Range of Sizes Now Accommodates More Patient Anatomies

Doctors in New South Wales and Victoria Become First in Australia to Treat Patients with Aortic Aneurysms Using GORE® DrySeal Sheath
03 August 2010 - Revolutionary Device Delivers Consistent Performance, Better Control, and Minimized Blood Loss During Minimally Invasive Endovascular Procedure


Gore Global Registry for Endovascular Aortic Treatment Reaches 2,500 Enrolled Patients
28 February 2015 - Milestone Achievement in Monitoring Patient Outcomes and Device Performance

W. L. Gore & Associates Named a Top U.S. Workplace
16 January 2013 - Company has appeared in every listing of the “100 Best Companies to Work For”

GORE® EXCLUDER® Conformable AAA Endoprosthesis Receives Approval for Clinical Study in the US and Japan
16 June 2015 - Device designed to bring endovascular therapy options to patients previously considered untreatable

Gore REVISE Study Receives Conditional Approval From FDA
12 July 2007 - Conditional approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with GORE VIABAHN® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates.

GORE® Septal Occluder Honored as Best In Show and Gold Winner in the 2013 Medical Design Excellence Awards
26 June 2013 - Recognition for Innovation in Expanding Treatment Options for Patients

Royal Sussex County Hospital First in the UK to Enroll a Patient in the Gore REDUCE Clinical Study for the Indication of Patent Foramen Ovale (PFO) Closure
01 November 2011 - International study to demonstrate safety, effectiveness of GORE® HELEX® Septal Occluder for PFO closure in patients with a history of cryptogenic stroke

Gore Receives Zero Reports of Erosion Associated With GORE® HELEX® Septal Occluder
22 August 2011 - W. L. Gore & Associates (Gore) today reported that it has received zero accounts of erosion of the aortic root or the free wall of the atrium associated with the worldwide use of the GORE® HELEX® Septal Occluder.

First Patient Enrolled in Gore Early TIPS for Ascites Study at Indiana University Hospital
25 April 2011 - Clinical Study to Examine Effects of Early Intervention with Transjugular Intrahepatic Portosystemic Shunt (TIPS) Therapy on Transplant-Free Liver Disease Survival Rates

First Patient Enrolled in Gore TAG Thoracic Branch Endoprosthesis LSA Feasibility Study
27 January 2014 - Multi-Center Study to Assess Feasibility of Gore Device to Treat Historically Challenging Patient Population

Gore Presents Astronaut and Scientist Mae C. Jemison, MD, as Keynote Speaker at Women in Vascular Leadership Luncheon
18 March 2014 - The pioneering Dr. Jemison, who flew aboard the Space Shuttle Endeavour, will address vascular surgeons at the 2014 SCVS symposium in Carlsbad, Calif.

Gore Global Registry for Endovascular Aortic Treatment Reaches 2,500 Enrolled Patients - English

Conformable GORE® TAG® Thoracic Endoprosthesis, GORE® EXCLUDER® AAA Endoprosthesis, GORE® EXCLUDER® Iliac Branch Endoprosthesis, GORE® TAG® Thoracic Endoprosthesis

(47 KB, 2 pages, .pdf)


Showing 51 to 75 of 136 Results
Page 1 | 2 | 3 | 4 | 5 | 6